William F. Hahne

Treatment parameters modulating regression of human melanoma xenografts by an antibody–drug conjugate (CR011-vcMMAE) targeting GPNMB

M. Jeffers, H. Lichenstein, M. Torgov, 2007, Cancer Chemotherapy and Pharmacology.

Single‐Dose, Placebo‐Controlled, Phase I Study of Oral Dolasetron

C. Benedict, W. Hahne, M. Cramer, 1996, Pharmacotherapy.

A Double‐Blind, Placebo‐Controlled, Dose‐Ranging Safety Evaluation of Single‐Dose Intravenous Dolasetron in Healthy Male Volunteers

C. Benedict, T. Hunt, W. Hahne, 1995, Journal of clinical pharmacology.

Randomized, double blind, dose‐response trial across four oral doses of dolasetron for the prevention of acute emesis after moderately emetogenic chemotherapy

J. Hainsworth, E. Rubenstein, R. Gralla, 1997 .

Single‐ and multiple‐dose pharmacokinetics of oral dolasetron and its active metabolites in healthy volunteers: part 2

S. Weir, T. Arumugham, W. Hahne, 1999, Biopharmaceutics & drug disposition.

Pharmacokinetics of Dolasetron after Oral and Intravenous Administration of Dolasetron Mesylate in Healthy Volunteers and Patients with Hepatic Dysfunction

W. Hahne, L. Martin, D. Dimmitt, 1997, Journal of clinical pharmacology.

Randomized Comparison of the Antiemetic Efficacy of a Serotonin Type 3 Receptor Antagonist (MDL 72,222) with a High‐Dose Metoclopramide Regimen

H. Homesley, S. Lentz, L. Woodlief, 1993, American Journal of Clinical Oncology.